March 6, 2019 / 6:24 AM / 17 days ago

BRIEF-FDA Accepts Genentech's Supplemental New Drug Application For Xofluza

March 6 (Reuters) - Genentech:

* FDA ACCEPTS GENENTECH’S SUPPLEMENTAL NEW DRUG APPLICATION FOR XOFLUZA (BALOXAVIR MARBOXIL) FOR THE TREATMENT OF INFLUENZA IN PEOPLE AT HIGH RISK OF COMPLICATIONS

* GENENTECH- XOFLUZA WOULD BE FIRST ANTIVIRAL MEDICINE APPROVED SPECIFICALLY FOR HIGH-RISK POPULATION

* GENENTECH - FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL BY NOVEMBER 4, 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below